

**November 05, 2025**

**BSE Limited**

Department of Corporate Relationship  
1<sup>st</sup> Floor, New Trade Ring, Rotunda Building  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400001  
Scrip Code: 524742

**National Stock Exchange of India Ltd**

Department of Corporate Services  
Exchange Plaza, 5<sup>th</sup> Floor,  
C-1, Block G, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
Scrip Code: CAPLIPOINT.

Dear Sir/Madam,

**Sub: Outcome of Board Meeting**

Further to our intimation dated 29<sup>th</sup> October, 2025 we wish to inform you that the Board of Directors, at its meeting held today i.e. 5<sup>th</sup> November 2025, has, inter-alia approved the following:

1. Approved the Un-audited standalone and consolidated financial results and the Limited Review Report **(Annexure-1)** of the Company as per Indian Accounting Standards for the quarter and half year ended 30<sup>th</sup> September, 2025. We also enclose a Press Release issued by the Company **(Annexure 2)** and an investor presentation in this regard **(Annexure 3)**.
2. Approved the Appointment of Mr. Ashok Partheeban (DIN: 02507261) as an Additional Director and Vice-Chairman of the Company with effect from 5<sup>th</sup> November 2025 and whose term is liable to retirement by rotation, subject to the approval of shareholders.
3. Approved the appointment of Mr. Vivek Partheeban (DIN: 02507289) as an Additional Director and Vice-Chairman of the Company with effect from 5<sup>th</sup> November 2025 whose term is liable to retirement by rotation, subject to the approval of shareholders. Consequent to this appointment, Mr. Vivek Partheeban had also relinquished his position of Chief Operating Officer, a Senior Management (SMP) position of the Company, with immediate effect.
4. Approved the appointment of Dr. K C John (DIN: 01067374) as an Additional Director (Non-Executive Independent) of the Company with the tenure of Independent Director as five years with effect from 5<sup>th</sup> November 2025, subject to the approval of shareholders.

The meeting commenced at 10.55 A.M and concluded at 1.15 P.M.

Kindly take the same on your records.

Sincerely Yours

**For Caplin Point Laboratories Limited**

**Venkatram G**  
**General Counsel & Company Secretary**  
**Membership No. A23989**  
Encl: A/a

**Independent Auditor's Review Report on Unaudited Standalone Quarterly and Year to Date Financial Results of Caplin Point Laboratories Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To,

**The Board of Directors  
Caplin Point Laboratories Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Caplin Point Laboratories Limited ("the Company")** for the quarter ended 30<sup>th</sup> September, 2025 and for the period from 1<sup>st</sup> April, 2025 to 30<sup>th</sup> September, 2025 ("**the Statement**") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ("SRE") 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India ("ICAI"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Chennai

Date : November 5, 2025



**For Brahmayya & Co.,  
Chartered Accountants**  
Firm Regn No. 000511S

**N. Sri Krishna  
Partner**


Membership No. 026575

UDIN : **25026575BMLHAD8605**



CAPLIN POINT LABORATORIES LIMITED							
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025							
Particulars	Quarter Ended			Half year Ended		Year Ended	
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025	
	(1)	(2)	(3)	(4)	(5)	(6)	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
₹ In Crores							
<b>Income:</b>							
<b>I</b> Revenue from operations	175.18	182.57	207.93	357.75	393.57	752.41	
<b>II</b> Other income	59.22	32.03	43.01	91.25	64.51	134.59	
<b>III</b> Total Income (I+II)	234.40	214.60	250.94	449.00	458.08	887.00	
<b>IV</b> Expenses:							
a. Cost of materials consumed	34.92	38.62	32.72	73.54	69.10	136.64	
b. Purchase of traded goods	21.21	13.18	24.36	34.39	40.54	77.17	
c. Changes in inventories of finished goods, stock in trade and work in progress	2.05	6.27	4.70	8.32	12.51	24.36	
d. Employee benefits expense	11.54	9.63	12.99	21.17	23.85	52.13	
e. Finance costs	0.05	0.04	0.02	0.09	0.04	0.12	
f. Depreciation & Amortisation Expense	6.02	6.14	6.49	12.16	12.67	24.77	
g. Other Expenses	29.61	28.26	35.00	57.87	68.03	130.14	
<b>Total Expenses</b>	<b>105.40</b>	<b>102.14</b>	<b>116.28</b>	<b>207.54</b>	<b>226.74</b>	<b>445.33</b>	
<b>V</b> Profit before exceptional items and Tax (III-IV)	<b>129.00</b>	<b>112.46</b>	<b>134.66</b>	<b>241.46</b>	<b>231.34</b>	<b>441.67</b>	
<b>VI</b> Exceptional items	-	-	-	-	-	-	
<b>VII</b> Profit Before Tax (V-VI)	<b>129.00</b>	<b>112.46</b>	<b>134.66</b>	<b>241.46</b>	<b>231.34</b>	<b>441.67</b>	
<b>VIII</b> Tax Expenses							
(1) Current Tax	26.77	26.91	29.15	53.68	53.72	102.90	
(2) Deferred Tax	(0.36)	(0.34)	(0.23)	(0.70)	(0.66)	(0.72)	
<b>Total Tax Expenses</b>	<b>26.41</b>	<b>26.57</b>	<b>28.92</b>	<b>52.98</b>	<b>53.06</b>	<b>102.18</b>	
<b>IX</b> Net Profit for the period (VII-VIII)	<b>102.59</b>	<b>85.89</b>	<b>105.74</b>	<b>188.48</b>	<b>178.28</b>	<b>339.49</b>	
<b>X</b> Other Comprehensive Income/ (Loss) - Net of Tax							
A. Items that will not be re-classified to profit or loss							
i) Remeasurements of Defined Benefit Plan	0.67	-	0.16	0.67	0.16	(0.13)	
ii) Income tax relating to these items	(0.17)	-	(0.04)	(0.17)	(0.04)	0.03	
<b>XI</b> Total Comprehensive Income For The Period (IX+X)	<b>103.09</b>	<b>85.89</b>	<b>105.86</b>	<b>188.98</b>	<b>178.40</b>	<b>339.39</b>	
<b>XII</b> Paid up Equity Share Capital (Face value of shares of Rs 2/- each)	15.20	15.20	15.20	15.20	15.20	15.20	
<b>XIII</b> Other equity						1,685.73	
<b>XIV</b> Earnings Per Share (EPS) of Face value Rs 2/- per Equity share*							
(a) Basic (in Rupees)	13.50	11.30	13.92	24.80	23.47	44.67	
(b) Diluted (in Rupees)	13.45	11.26	13.85	24.71	23.35	44.47	
	*(Not Annualised)	*(Not Annualised)	*(Not Annualised)	*(Not Annualised)	*(Not Annualised)	*(Not Annualised)	*(Annualised)

See Accompanying notes to Financial Results





## CAPLIN POINT LABORATORIES LIMITED


## STANDALONE BALANCE SHEET AS AT SEPTEMBER 30, 2025

(All amounts mentioned are in ₹ Crores unless otherwise stated)

Particulars	(Unaudited)	(Audited)
	As at September 30, 2025	As at March 31, 2025
<b>ASSETS</b>		
<b>(1) Non-Current Assets</b>		
(a) Property, plant and equipment	213.85	201.59
(b) Capital work-in-progress	18.91	20.64
(c) Intangible assets	1.64	2.10
(d) Right of Use Assets	2.50	1.57
(e) Financial assets		
(i) Investments	512.84	491.11
(ii) Loans	257.20	245.80
(iii) Other Financial Assets	26.08	18.81
(f) Income tax assets (Net)	1.34	2.90
(g) Other Non-current Assets	6.42	4.27
<b>Sub-total-Non current assets</b>	<b>1,040.78</b>	<b>988.79</b>
<b>(2) Current Assets</b>		
(a) Inventories	60.03	66.26
(b) Financial assets		
(i) Investments	383.25	311.33
(ii) Trade receivables	249.87	175.33
(iii) Cash and cash equivalents	69.57	99.64
(iv) Bank balances other than (iii) above	115.29	115.07
(v) Other Financial Assets	25.33	25.92
(c) Other current assets	40.24	32.14
<b>Sub-total-Current assets</b>	<b>943.58</b>	<b>825.69</b>
<b>Total</b>	<b>1,984.36</b>	<b>1,814.48</b>
<b>EQUITY AND LIABILITIES</b>		
<b>(1) Equity</b>		
(a) Equity share capital	15.20	15.20
(b) Other equity	1,828.42	1,685.73
<b>Sub-total-Equity</b>	<b>1,843.62</b>	<b>1,700.93</b>
<b>(2) Liabilities</b>		
<b>(A) Non-Current Liabilities</b>		
(a) Financial liabilities		
(i) Lease Liabilities	1.78	1.13
(b) Deferred tax liabilities (Net)	8.72	9.25
(c) Other non current liabilities	2.43	2.47
(d) Provisions	0.11	0.85
<b>Sub-total-Non current liabilities</b>	<b>13.04</b>	<b>13.70</b>
<b>(B) Current Liabilities</b>		
(a) Financial liabilities		
(i) Trade payables		
(a) total outstanding dues of micro and small enterprises	1.63	1.78
(b) total outstanding dues other than micro and small enterprises	57.22	59.18
(ii) Lease Liabilities	0.77	0.53
(iii) Other financial Liabilities	19.17	16.50
(b) Provisions	12.79	10.68
(c) Other Current liabilities	36.12	11.18
<b>Sub-total-Current liabilities</b>	<b>127.70</b>	<b>99.85</b>
<b>Total</b>	<b>1,984.36</b>	<b>1,814.48</b>

For  
Identification  
Only

CHARTERED ACCOUNTANTS





## CAPLIN POINT LABORATORIES LIMITED

## STANDALONE STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2025

(All amounts are in ₹ Crores unless otherwise stated)

Particulars	Unaudited	Unaudited
	For the half year ended Sept 30, 2025	For the half year ended Sept 30, 2024
<b>A. Cash Flow from Operating Activities</b>		
Profit before tax	241.46	231.34
Adjustments for:		
Depreciation and Amortisation expense	12.16	12.67
Finance costs	0.09	0.04
Government grant	(0.29)	(0.33)
(Profit)/Loss on sale/disposal of property, plant and equipment	2.60	0.02
Employee Stock Option Scheme Expense	(1.82)	2.98
Net Unrealised Foreign Exchange Fluctuation Loss (Gain)	(6.15)	(3.40)
Fair value loss on financial instruments through profit or loss	(2.29)	0.07
Realised gain on Financial Assets	(2.24)	(2.08)
Dividend Income	(31.75)	(20.40)
Interest Income	(41.46)	(35.55)
<b>Operating Profit before Working Capital changes</b>	<b>170.31</b>	<b>185.36</b>
Adjustments for :		
(Increase) / Decrease in Inventories	6.23	15.63
(Increase) / Decrease in Trade receivables	(68.56)	(46.19)
(Increase) / Decrease in Other Assets	(8.10)	(4.75)
(Increase) / Decrease in Other Financial assets	0.23	(0.71)
Increase / (Decrease) in Trade payables ,Other Liabilities & Provisions	29.16	(19.93)
<b>Cash Generated from Operations</b>	<b>129.27</b>	<b>129.41</b>
Income tax Paid	(52.12)	(47.19)
<b>Net Cash inflow / (outflow) from Operating activities</b>	<b>77.15</b>	<b>82.22</b>
<b>B. Cash Flow from Investing Activities</b>		
Sale / (Purchase) of Investments	(90.23)	(130.28)
Investment in Bank Deposits & Inter Corporate Deposits	(5.85)	-
Investment in Subsidiaries	-	1.39
Loan- repayment by/(given to) Subsidiary (net)	(11.40)	20.50
(Increase)/Decrease in Other Bank Balances	0.04	3.85
Sale / (Purchase) of property, plant and equipment (Including CWIP)	(28.64)	(11.58)
Interest received	40.40	32.12
Dividend received	31.75	20.40
Realised gain on Financial Assets	2.24	2.08
<b>Net Cash inflow/(outflow) from Investing activities</b>	<b>(61.69)</b>	<b>(61.52)</b>
<b>C. Cash Flow from Financing Activities</b>		
Proceeds from exercise of employee stock options	-	0.01
Interest paid (Including interest on Lease liability)	(0.09)	(0.04)
Dividend paid	(45.61)	(18.98)
<b>Net Cash inflow / (outflow) from Financing activities</b>	<b>(45.70)</b>	<b>(19.01)</b>
<b>Net increase / (decrease) in cash and cash equivalents during the period D=(A+B+C)</b>	<b>(30.24)</b>	<b>1.69</b>
<b>Cash and Cash Equivalents as at the beginning of the period (E)</b>	<b>99.64</b>	<b>80.64</b>
Effect of exchange rate changes on cash and cash equivalents (F)	0.17	1.15
<b>Cash and Cash Equivalents as at the end of the period (G=D+E+F)</b>	<b>69.57</b>	<b>83.48</b>
Less: Bank Balance in Unspent CSR Account (H)	0.01	0.15
<b>Net Cash and Cash Equivalents as at the end of the period (I=G-H)</b>	<b>69.56</b>	<b>83.33</b>

For  
Identification  
Only

★ BRAHMAYYA & CO. ★  
★ CHARTERED ACCOUNTANTS ★






## CAPLIN POINT LABORATORIES LIMITED

### Standalone Notes:

- 1) The above Standalone financial Results for the quarter and half year ended September 30, 2025 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 5, 2025 and reviewed by the Statutory Auditors.
- 2) The Unaudited Standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3) The Company is engaged in the sole activity of carrying on the business of "Pharmaceutical Formulations" and therefore no separate segment reporting is applicable to the Company.
- 4) Other Income and Profit Before Tax includes:

Particulars	₹ in Crores					
	Quarter Ended			Half Year Ended		Year Ended
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
Dividend from wholly owned subsidiary Caplin Point Far East Limited	23.63	8.12	20.40	31.75	20.40	35.53

- 5) During the quarter and half year ended September 30, 2025, the Company has allotted NIL equity shares of ₹2/- each under the Employees Stock Option Schemes and the total number of equity shares of the Company stands at 7,60,11,696 as of September 30, 2025, and 7,60,11,696 as at September 30, 2024. The Company had allotted 1,400 shares and 69,950 shares during the quarter ended and half year ended September 30, 2024, respectively.
- 6) The Shareholders, at their General Meeting held on September 22, 2025 approved a final dividend of ₹ 3.00/- (Rs. Three Only) per equity share (150 %) for the financial year 2024-25 and was paid to the shareholders on September 29, 2025.  
The total dividend for the financial year 2024-25 including the Interim and Final dividend is ₹ 6.00/- (Rs. Six Only) per equity share (300%) of the face value of ₹ 2 each.
- 7) Previous periods' figures have been regrouped / reclassified to be in conformity with current period's classification / disclosure, wherever necessary.



Place: Chennai  
Date: November 5, 2025

For and on behalf of the Board

Dr. Sridhar Ganesan  
Managing Director





**Independent Auditor's Review Report on Unaudited Consolidated Quarterly and Year to Date Financial Results of Caplin Point Laboratories Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

To,  
The Board of Directors  
Caplin Point Laboratories Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Caplin Point Laboratories Limited ("the Holding Company")** and its subsidiaries (the Holding Company and its subsidiaries together referred to as **"the Group"**) and its share in the net profit / (loss) after tax and total comprehensive income / loss of its associate for the quarter ended 30<sup>th</sup> September, 2025 and for the period from 1<sup>st</sup> April, 2025 to 30<sup>th</sup> September, 2025 (**"the Statement"**) being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements ("SRE") 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India ("ICAI"). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the SEBI under Regulation 33(8) of the (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The statement includes results of the following entities:

**Subsidiary Companies**

Name of the Entity	Relationship
Caplin Steriles Limited, India	Subsidiary
Argus Salud Pharma LLP, India	Subsidiary
Caplin One Labs Limited, India (Formerly known as Caplin Onco Limited)	Wholly owned subsidiary
Caplin Point Far East Limited, Hong Kong	Wholly owned subsidiary
Caplin Point (S) Pte. Ltd, Singapore	Wholly owned subsidiary



**Step Down Subsidiaries (Subsidiaries of Caplin Point Far East Limited, Hong Kong)**

Name of the Entity	Relationship
Caplin Point EL Salvador, S.A. DE C.V., El Salvador	Step Down Subsidiary
Nuevos Eticos Neo Ethicals S.A, Guatemala	Step Down Subsidiary
Neoethicals CIA.LTDA, Ecuador	Step Down Subsidiary
Drogueria Saimed de Honduras S.A., Honduras	Step Down Subsidiary
Neo Ethicals S.A, Nicaragua	Step Down Subsidiary
Caplin Point Laboratories Colombia SAS, Colombia	Step Down Subsidiary
Neoethicals Chile SpA	Step Down Subsidiary
Triwin Pharma S.A DE C.V Mexico	Step Down Subsidiary

**Step Down Subsidiary (Subsidiary of Caplin Steriles Limited, India)**

Name of the Entity	Relationship
Caplin Steriles USA Inc., USA	Step Down Subsidiary

**Associate Company of Caplin Steriles Limited**

Name of the Entity	Relationship
Sunsole Solar Private Limited	Associate

- Based on our review conducted and procedures performed as stated in paragraph 3 above, and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- We did not review the interim financial results of five subsidiaries and eight step-down subsidiaries; whose interim financial results reflect total assets of Rs. 2,942.65 Crores as at 30<sup>th</sup> September, 2025 and total revenues of Rs. 442.88 Crores and Rs. 908.29 Crores, total net profit after tax of Rs. 72.21 Crores and Rs. 140.08 Crores and total comprehensive income of Rs. 72.75 Crores and Rs. 140.62 Crores for the Quarter ended 30<sup>th</sup> September, 2025 and for the period from 1<sup>st</sup> April, 2025 to 30<sup>th</sup> September, 2025, respectively and net cash outflow of Rs. 61.18 Crores for the period from 1<sup>st</sup> April, 2025 to 30<sup>th</sup> September, 2025, as considered in the Statement. The Statement also includes the Group's share of net profit after tax and total comprehensive income of Rs. 0.03 Crores and Rs. 0.05 Crores for the quarter ended September 30, 2025 and for the period from 1<sup>st</sup> April, 2025 to 30<sup>th</sup>



September, 2025, respectively in respect of one associate, based on their interim financial results. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in Paragraph 3 above.

Our conclusion on the statement is not modified in respect of this matter.

7. The Statement includes the interim financial results of one step-down subsidiary which has not been reviewed by their auditors, whose interim financial results reflect total assets of Rs. 0.48 Crores as at 30<sup>th</sup> September, 2025 and total revenue Nil, net loss after tax and total comprehensive income of Rs. 0.86 Crores and Rs. 1.10 Crores for the quarter ended 30<sup>th</sup> September, 2025 and for the period from 1<sup>st</sup> April, 2025 to 30<sup>th</sup> September, 2025, respectively and net cash outflow of Rs. 0.06 Crores for the period from 1<sup>st</sup> April, 2025 to 30<sup>th</sup> September, 2025, as considered in the Statement. According to the information and explanations given to us by the management, these interim financial results of aforesaid subsidiary is not material to the Group.

Our conclusion on the statement is not modified in respect of the above matter.

Place : Chennai

Date : November 5, 2025



**For Brahmayya & Co.,**  
**Chartered Accountants**  
Firm Regn No: 000511S

**N. Sri Krishna**  
**Partner**

Membership No.026575

UDIN : 25026575BMLHAE7790



CAPLIN POINT LABORATORIES LIMITED							
STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025							
Particulars	Quarter Ended			Half Year Ended		Year Ended	
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025	
	(1)	(2)	(3)	(4)	(5)	(6)	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
₹ in Crores							
<b>Income:</b>							
I Revenue from operations	534.04	510.22	483.10	1,044.26	942.06	1,937.47	
II Other income	30.37	23.14	20.77	53.51	39.33	96.43	
III <b>Total Income (I+II)</b>	<b>564.41</b>	<b>533.36</b>	<b>503.87</b>	<b>1,097.77</b>	<b>981.39</b>	<b>2,033.90</b>	
<b>IV Expenses:</b>							
a. Cost of materials consumed	92.34	73.51	69.23	165.85	127.81	248.45	
b. Purchase of traded goods	121.68	113.50	126.07	235.18	242.78	483.83	
c. Changes in inventories of finished goods, stock in trade and work in progress	(3.72)	8.23	(6.48)	4.51	3.71	38.56	
d. Employee benefits expense	47.23	43.16	44.29	90.39	84.44	177.72	
e. Finance costs	0.16	0.18	0.21	0.34	0.26	0.61	
f. Depreciation & Amortisation Expense	18.40	16.29	16.76	34.69	32.72	65.96	
g. Other Expenses	87.34	94.06	85.23	181.40	166.75	341.98	
<b>Total Expenses</b>	<b>363.43</b>	<b>348.93</b>	<b>335.31</b>	<b>712.36</b>	<b>658.47</b>	<b>1,357.11</b>	
<b>V Profit before share of profit in Associate, Exceptional Items and tax (III-IV)</b>	<b>200.98</b>	<b>184.43</b>	<b>168.56</b>	<b>385.41</b>	<b>322.92</b>	<b>676.79</b>	
VI Share of Profit/(Loss) in Associate	0.02	0.03	(0.10)	0.05	(0.08)	(0.01)	
VII Exceptional items	-	-	-	-	-	-	
VIII <b>Profit Before Tax (V+VI+VII)</b>	<b>201.00</b>	<b>184.46</b>	<b>168.46</b>	<b>385.46</b>	<b>322.84</b>	<b>676.78</b>	
<b>IX Tax Expenses</b>							
(1) Current Tax	36.53	33.10	32.46	69.63	61.84	125.33	
(2) Deferred Tax	4.24	0.60	5.19	4.84	5.27	10.36	
<b>Total Tax Expenses</b>	<b>40.77</b>	<b>33.70</b>	<b>37.65</b>	<b>74.47</b>	<b>67.11</b>	<b>135.69</b>	
X <b>Net Profit for the period (VIII - IX)</b>	<b>160.23</b>	<b>150.76</b>	<b>130.81</b>	<b>310.99</b>	<b>255.73</b>	<b>541.09</b>	
<b>XI Other Comprehensive Income - Net of Tax</b>							
A. Items that will not be re-classified to profit or loss							
i) Remeasurements of Defined Benefit Plan	1.34	-	0.38	1.34	0.38	0.14	
ii) Income tax relating to these items	(0.34)	-	(0.09)	(0.34)	(0.09)	(0.04)	
B. Items that will be re-classified to profit or loss							
i) Exchange difference in translating the financial statements of foreign operations	46.54	0.36	1.04	46.90	5.72	26.97	
XII <b>Total Comprehensive Income For The Period (X + XI)</b>	<b>207.77</b>	<b>151.12</b>	<b>132.14</b>	<b>358.89</b>	<b>261.74</b>	<b>568.16</b>	
<b>XIII Profit attributable to:</b>							
Owners of the Company	154.45	152.80	130.80	307.25	254.77	536.31	
Non- controlling interests	5.78	(2.04)	0.01	3.74	0.96	4.78	
	<b>160.23</b>	<b>150.76</b>	<b>130.81</b>	<b>310.99</b>	<b>255.73</b>	<b>541.09</b>	
<b>XIV Total Comprehensive Income For The Period attributable to</b>							
Owners of the Company	201.99	153.16	132.13	355.15	260.78	563.38	
Non- controlling interests	5.78	(2.04)	0.01	3.74	0.96	4.78	
	<b>207.77</b>	<b>151.12</b>	<b>132.14</b>	<b>358.89</b>	<b>261.74</b>	<b>568.16</b>	
XV Paid up Equity Share Capital (Face value of share of Rs 2/- each)	15.20	15.20	15.20	15.20	15.20	15.20	
XVI Other equity excluding Non-controlling interest						2,835.29	
<b>XVII Earnings Per Share (EPS) of Face value Rs 2/- per Equity share*</b>							
(a) Basic (in Rupees)	20.32	20.10	17.22	40.42	33.54	70.57	
(b) Diluted (in Rupees)	20.25	20.03	17.12	40.28	33.36	70.25	
	*(Not Annualised)	*(Not Annualised)	*(Not Annualised)	*(Not Annualised)	*(Not Annualised)	*(Annualised)	

See Accompanying notes to Financial Results





**CAPLIN POINT LABORATORIES LIMITED**  
**CONSOLIDATED BALANCE SHEET AS AT SEPTEMBER 30, 2025**  
(All amounts mentioned are in ₹ Crores unless otherwise stated)

Particulars	(Unaudited)	(Audited)
	As at September 30, 2025	As at March 31, 2025
<b>ASSETS</b>		
<b>(1) Non-Current Assets</b>		
(a) Property, Plant and Equipment	523.48	530.32
(b) Capital work-in-progress	176.95	139.22
(c) Intangible assets	21.49	11.27
(d) Right of Use Assets	4.63	4.19
(e) Intangible Assets under development	5.61	4.28
(f) Financial Assets		
(i) Investments	266.36	279.13
(ii) Other Financial Assets	84.35	22.20
(g) Income tax assets (Net)	8.13	13.09
(h) Deferred Tax Assets (Net)	-	2.23
(i) Other Non-Current assets	84.80	67.97
<b>Sub-total-Non current assets</b>	<b>1,175.80</b>	<b>1,073.90</b>
<b>(2) Current Assets</b>		
(a) Inventories	329.43	336.10
(b) Financial Assets		
(i) Investments	370.11	311.33
(ii) Trade Receivables	694.45	632.49
(iii) Cash and Cash equivalents	108.26	199.45
(iv) Bank balances other than (iii) above	538.83	391.96
(v) Other Financial Assets	59.32	57.37
(c) Other Current Assets	227.72	205.25
<b>Sub-total-Current assets</b>	<b>2,328.12</b>	<b>2,133.95</b>
<b>Total</b>	<b>3,503.92</b>	<b>3,207.85</b>
<b>EQUITY AND LIABILITIES</b>		
<b>(1) Equity</b>		
Equity Share capital	15.20	15.20
Instruments entirely equity in nature	74.58	74.58
Other Equity	3,069.57	2,760.71
<b>Equity attributable to shareholders of the company</b>	<b>3,159.35</b>	<b>2,850.49</b>
Non controlling interest	39.64	35.90
<b>Sub-total-Equity</b>	<b>3,198.99</b>	<b>2,886.39</b>
<b>(2) Liabilities</b>		
<b>(A) Non-Current Liabilities</b>		
(a) Financial Liabilities		
(i) Lease Liabilities	3.19	2.91
(b) Deferred Tax Liabilities (Net)	2.73	-
(c) Provisions	1.05	1.74
(d) Other non current liabilities	13.06	10.82
<b>Sub-total-Non current liabilities</b>	<b>20.03</b>	<b>15.47</b>
<b>(B) Current Liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	0.49	0.55
(ii) Trade Payables		
(a) total outstanding dues of micro and small enterprises	2.25	2.28
(b) total outstanding dues other than (ii) (a) above	206.90	215.30
(iii) Lease Liabilities	1.63	1.56
(iv) Other financial Liabilities	44.39	45.26
(b) Provisions	17.74	23.58
(c) Other Current Liabilities	11.50	17.46
<b>Sub-total-Current liabilities</b>	<b>284.90</b>	<b>305.99</b>
<b>Total</b>	<b>3,503.92</b>	<b>3,207.85</b>






**CAPLIN POINT LABORATORIES LIMITED**  
**CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2025**  
(All amounts are in ₹ Crores unless otherwise stated)

Particulars	(Unaudited)	(Unaudited)
	For the half year ended Sep 30, 2025	For the half year ended Sep 30, 2024
<b>A. Cash Flow from Operating Activities</b>		
Profit before tax	385.46	322.84
Adjustments for:		
Depreciation and Amortisation expense	34.69	32.72
Finance costs	0.34	0.26
Government grant	(1.18)	(0.77)
(Profit)/Loss on sale/disposal of property, plant and equipment	2.72	0.05
Employee Stock option Scheme Expense	(0.68)	4.37
Net Unrealised Foreign Exchange Fluctuation Loss (Gain)	(6.15)	(3.40)
Fair value (gain)/loss on financial instruments through profit or loss	(2.68)	(0.03)
Realised gain on Financial Assets	(2.69)	(2.07)
Share of Profit in Associate	(0.05)	0.08
Interest income	(36.73)	(28.79)
<b>Operating Profit before Working Capital changes</b>	<b>373.05</b>	<b>325.26</b>
Adjustments for :		
(Increase) / Decrease in inventories	9.94	35.95
(Increase) / Decrease in Trade receivables	(55.24)	(73.00)
(Increase) / Decrease in Other Financial assets	(7.50)	(2.26)
(Increase) / Decrease in Other assets	(20.65)	(29.22)
Increase / (Decrease) in Trade payables, Other Liabilities & Provisions	(28.09)	(15.05)
Impact of Foreign currency translation	46.90	5.72
<b>CASH GENERATED FROM OPERATIONS</b>	<b>318.41</b>	<b>247.40</b>
Income tax Paid (Net)	(64.67)	(61.58)
<b>Net Cash inflow / (outflow) from Operating activities (A)</b>	<b>253.74</b>	<b>185.82</b>
<b>B. Cash Flow from Investing Activities</b>		
Payment for Acquisition of subsidiaries (Net)	(0.05)	
Sale / (Purchase) of investments	(43.27)	(138.30)
Investment / (Redemption) in Bank Deposits & Inter corporate Debenture	(50.85)	-
(Increase) / Decrease in Other Bank Balances	(146.86)	56.67
Sale / (Purchase) of property, plant and equipment (Including CWIP)	(93.88)	(77.23)
Interest received	33.13	26.84
Realised gain on Financial Assets	2.69	2.07
<b>Net Cash inflow / (outflow) from Investing activities (B)</b>	<b>(299.09)</b>	<b>(129.95)</b>
<b>C. Cash Flow from Financing Activities</b>		
Proceeds from exercise of employee stock options	-	0.01
Increase / (Decrease) in Long and Short term Borrowings	(0.06)	0.35
Interest paid (Including interest on Lease liability)	(0.34)	(0.26)
Dividend paid	(45.61)	(18.98)
<b>Net Cash inflow / (outflow) from Financing activities (C)</b>	<b>(46.01)</b>	<b>(18.88)</b>
<b>Net increase / (decrease) in cash and cash equivalents during the period (D=A+B+C)</b>	<b>(91.36)</b>	<b>36.99</b>
<b>Cash and Cash Equivalents as at the beginning of the period (E)</b>	<b>199.45</b>	<b>138.70</b>
Effect of exchange rate changes on cash and cash equivalents (F)	0.17	1.15
<b>Cash and Cash Equivalents as at the end of the period (G=D+E+F)</b>	<b>108.26</b>	<b>176.84</b>
Less: Bank Balance in Unspent CSR Account (H)	0.01	0.15
<b>Net Cash and Cash Equivalents as at the end of the period (I=G-H)</b>	<b>108.25</b>	<b>176.69</b>


BRAHMAYYA & CO.  
For Identification Only  
CHARTERED ACCOUNTANTS





**CAPLIN POINT LABORATORIES LIMITED**  
**Segment Information- Revenues and Results**

Particulars	Quarter Ended			Half year Ended		Year Ended
	30.09.2025	30.06.2025	30.09.2024	30.09.2025	30.09.2024	31.03.2025
	(1)	(2)	(3)	(4)	(5)	(6)
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
₹ In Crores						
<b>1) Segment revenue (Total Revenue)</b>						
Rest of the World	427.08	403.53	390.67	830.61	771.71	1,582.96
USA	106.96	106.69	92.43	213.65	170.35	354.51
Unallocated	30.37	23.14	20.77	53.51	39.33	96.43
<b>Total</b>	<b>564.41</b>	<b>533.36</b>	<b>503.87</b>	<b>1,097.77</b>	<b>981.39</b>	<b>2,033.90</b>
<b>2) Segment results (PBT)</b>						
Rest of the World	156.10	151.46	132.38	307.56	263.99	540.34
USA	14.53	9.86	15.31	24.39	19.52	40.01
Unallocated	30.37	23.14	20.77	53.51	39.33	96.43
<b>Total</b>	<b>201.00</b>	<b>184.46</b>	<b>168.46</b>	<b>385.46</b>	<b>322.84</b>	<b>676.78</b>
<b>3) Segment Assets</b>						
Rest of the World	1,588.42	1,488.80	1,324.01	1,588.42	1,324.01	1,448.25
USA	581.33	587.19	561.06	581.33	561.06	580.09
Unallocated	1,334.17	1,236.99	1,039.16	1,334.17	1,039.16	1,179.51
<b>Total</b>	<b>3,503.92</b>	<b>3,312.98</b>	<b>2,924.23</b>	<b>3,503.92</b>	<b>2,924.23</b>	<b>3,207.85</b>
<b>4) Segment Liabilities</b>						
Rest of the World	251.39	249.31	288.97	251.39	288.97	268.91
USA	53.54	50.34	60.65	53.54	60.65	53.28
Unallocated	-	-	-	-	-	-
<b>Total</b>	<b>304.93</b>	<b>299.65</b>	<b>349.62</b>	<b>304.93</b>	<b>349.62</b>	<b>322.19</b>






## CAPLIN POINT LABORATORIES LIMITED

### Consolidated Notes:

- 1) The above Consolidated Financial Results for the quarter and half year ended September 30, 2025, have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on November 5, 2025, and reviewed by the Statutory Auditors.
- 2) The unaudited Consolidated Financial Results of the Company has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3) The Group has identified two geographical segments as its reportable segments in accordance with Ind AS 108 – Operating Segments. Segment 1: Rest of the World. Segment 2: United States of America (USA). Accordingly, segment reporting has been presented along with the Consolidated results.
- 4) During the quarter and half year ended September 30, 2025, the Company has not allotted any equity shares under the Employees Stock Option Schemes and the total number of equity shares of the Company stands at 7,60,11,696 as of September 30, 2025, and 7,60,11,696 as at September 30, 2024. The Company had allotted 1400 shares and 69,950 shares during the quarter ended and half year ended September 30, 2024, respectively.
- 5) The Shareholders, at their General Meeting held on September 22, 2025 approved a final dividend of ₹ 3.00/- (Rs. Three Only) per equity share (150 %) for the financial year 2024-25 and was paid to the shareholders on September 29, 2025.  
The total dividend for the financial year 2024-25 including the Interim and Final dividend is ₹ 6.00/- (Rs. Six Only) per equity share (300%) of the face value of ₹ 2 each.
- 6) Previous periods' figures have been regrouped/reclassified to be in conformity with current period's classification/ disclosure, wherever necessary.



Place: Chennai  
Date: November 5, 2025

For and on behalf of the Board

Dr. Sridhar Ganesan  
Managing Director





**H1FY26 Total revenue of ₹1098 Crores, up 11.9% YoY, surpassing full-year revenue of ₹1,085 Crores in FY21.**

**H1FY26 PAT of ₹311 Crores, up 21.6% YoY surpassing full-year PAT of ₹308 Crores of FY22.**

**H1FY26 US market revenue of ₹221 Crores, recording 27% growth YoY.**

**Free Cash Reserves at ₹1,334 Crores; Liquid Assets at ₹2,358 Crores.**

**Chennai, 5<sup>th</sup> November 2025:** Caplin Point Laboratories Ltd. ("Caplin Point" or the "Company") (BSE: 524742 | NSE: CAPLIPOINT), a rapidly expanding and fully integrated pharmaceutical company with a leading market position in Latin America, today announced its financial performance for the quarter ended September 30, 2025.

**Consolidated Financial Performance for Q2 FY26 & H1FY26:**

₹ in Crores

Particulars	Q2 FY 26	Q2 FY 25	YoY (%)	Q1 FY 26	QoQ (%)	H1 FY26	H1 FY25	YoY (%)
Revenue from Operation	534.0	483.1	10.5%	510.2	4.7%	1,044.3	942.1	10.8%
Total Revenue	564.4	503.9	12.0%	533.4	5.8%	1,097.8	981.4	11.9%
Gross Profit	323.7	294.3	10.0%	315.0	2.8%	638.7	567.8	12.5%
Gross Margin %	60.6%	60.9%		61.7%		61.2%	60.3%	
EBITDA	219.5	185.5	18.3%	200.9	9.3%	420.4	355.9	18.1%
EBITDA Margin %	38.9%	36.8%		37.7%		38.3%	36.3%	
Profit Before Tax	201.0	168.5	19.3%	184.5	9.0%	385.5	322.8	19.4%
PBT Margin %	35.6%	33.4%		34.6%		35.1%	32.9%	
Profit after Tax	160.2	130.8	22.5%	150.8	6.3%	311.0	255.7	21.6%
PAT Margin	28.4%	26.0%		28.3%		28.3%	26.1%	

**Other Consolidated Financial Highlights for Q2 FY26 & H1FY26:**

- Q2FY26 Total revenue of ₹564 Crores, up 12.0% YoY, surpassing full-year FY18 revenue of Rs.553 Crores and Q2FY26 PAT of ₹160 Crores, up 22.5% YoY, surpassing full-year FY18 PAT of Rs.145 Crores.
- Gross Margin for H1 FY26 is 61.2% vs 60.3% in H1 FY25 and Q2FY26 is 60.6% vs 60.9% in Q2FY25 aided by new product launches across existing and new markets.
- EBITDA Margin for H1 FY26 is at 38.3% vs 36.3% in H1 FY25 and Q2FY26 is 38.9% vs 36.8% in Q2FY25.
- Basic EPS increased by 20.5% to ₹40.42 in H1 FY26 compared to ₹33.54 in H1 FY25.
- Cash Flow from Operations in H1 FY26 is ₹254 Crores vs ₹186 Crores in H1 FY25.
- Free Cash Flow is ₹160 Crores (after Capex investment of ₹94 Crores) in H1 FY26 as compared to ₹109 Crores (after capex investment of ₹77 Crores) in H1 FY25.
- Geographical revenue composition between Emerging Markets (Latin America & Africa) and US for H1 FY26 is in the range of 80% and 20% respectively.
- CSL's Revenue composition demonstrates a balanced mix of Product Supply and Milestone + Profit Share, with the split for H1 FY26 in the range of 80% and 20% respectively.



- As of 30<sup>th</sup> September 2025, Inventories are at ₹329 Crores - 53% Stock at the warehouses, close to the customer; In Transit 14%; 33% in India. Receivables are at 117 days.
- As of 30<sup>th</sup> September 2025, Free Cash reserves are at ₹1,334 Crores and Total Liquid Assets at ₹2,358 Crores.

### **Business Highlights for Q2 FY26:**

#### **Emerging Markets:**

- Caplin's dominant presence in Latin America continues to drive consistent growth across all metrics, with increase in Cashflow, Bottom Line and Top Line.
- Company has won tenders in Central American markets to the tune of \$10 million, to be supplied over 12-18 months.
- Company has filed its own internally developed GLP-1 products in all Central American countries of operations. To be expanded to all markets by H1-CY26, with revenues expected post patent expiry.
- Mexico Update – Company has filed 35+ products, with 20 approvals along with partners. Working on a pipeline of 80+ products, to be filed within the next 12 months, through Internal and China 2.0 partners.
- Chile Update – Company begins private market sales in Chile through newly established subsidiary/warehouse. Caplin already holds 125+ product licenses in Chile, with several more under review/pipeline.
- Company's "China 2.0" strategy gathers pace with its first Biosimilar product filing in Central America. Company has signed partnerships with 3 Chinese companies, granting access to 130+ approved ANDAs/MAs in the US and EU. These products will be extended to Mexico, Colombia and Chile, under Caplin's name.
- As part of alignment with global push towards "Onshored Manufacturing", Company finalizes procurement of land in Mexico and plans to manufacture Oral Liquids and Dermatology range of products, in the first phase.
- Company received necessary clearances at API unit for General Category products at Vizag. Procurement activities for scaling up of first few products underway. Site will go for Regulatory certifications by end of next year, with a target towards being backward integrated for 60% of all ANDAs in a few years.
- Construction ongoing at full swing at Oncology API site in Thervoy, near Chennai. Facility expected to be completed within 12 months and will cater to Company's budding Oncology business for Regulated and Emerging Markets.
- Update on Injectable section of Company's Oncology facility- Qualifications completed, with first set of Submission Batches for Injectable products set to be taken up in November.

#### **US & Regulated Markets:**

- Company successfully completes EU GMP reaudit in October '25, with NIL Critical Observations.
- Caplin Steriles Limited (CSL) continues consistent and profitable growth in H1 both B2B and B2C segments, aided by timely approvals. Order book remains healthy for H2 to outdo H1 comfortably.
- Company currently sits on 42 ANDA approvals with a further 10 ANDAs under review, setting the stage for strong growth in top and bottom line for the next few quarters.



- CSL has acquired 4 ANDAs from 3<sup>rd</sup> party companies, and is in advanced discussions to acquire more ANDAs, to augment growing presence in US and other Regulated markets.
- As part of Caplin's pattern of "growth through asset light model/outourced manufacturing", CSL starts to use high quality CMOs for certain products which are more cost-effective to outsource, even for US markets. Company plans to slowly move more products out, making capacity available for highly profitable products alone to be manufactured in-house.
- Company's Pre-Filled Syringes and Cartridges Line qualifications completed. Plans to file 11 Pre-Filled Syringe products within the next 12 months, which includes additional SKUs to existing ANDAs. Company will also file GLP-1 products from this line, in Emerging Markets such as Mexico, Colombia, Canada etc.
- Company takes up expansion of Pre-Mixed Injectable Bags line to more than 3X of the current capacity, owing to increased demand from markets and additional approvals.
- Company working on new pipeline of products using BFS technology for Ophthalmics – a niche area with very limited competition.
- To accommodate the growing requirements in Capacity, Automation and Compliance, the company has started working on COL-II, which is a facility that will house 5 Sterile product lines, capable of manufacturing all dosage forms including complex molecules. This facility will have state-of-the-art equipment with the latest requirements in Aseptic processing technology such as usage of Isolators, dedicated lines, etc. Company plans to commence operations with 2 lines within FY2027.
- **Update on Caplin Steriles USA Inc (CSU) - company's own label in the US:**
  - Company's front end achieves revenue of \$6.6 million from inception till date (around 12 months), with excellent profitability. CSU continues to show robust cashflows within the first year of operations.
  - CSU has launched 24 products till date, with a further 15+ products to be launched in FY26.
  - Company continues discussions with in-license more injectable and ophthalmic products from globally renowned CMO's, to augment its front end.
  - CSU sees good momentum with daily Direct and Indirect sales, through contracts established with all large and mid-sized Wholesalers in the US including Big 3, and with over 35+ IDNs/Health Systems.
  - Company plans to establish a separate retail arm focused on internal Ophthalmic products pipeline, in addition to Oral Solid products licensed from recent partnerships with Chinese companies with approved ANDAs.



**Commenting on the performance, Mr. C.C. Paarthipan, Chairman said:**

Consistency has been the cornerstone of Caplin's journey. We are pleased to report another strong set of results, fully aligned with our long-term growth path and guidance. Our unwavering focus on cashflows, profitability, and revenue growth continues across all segments of the business, complemented by an equally strong commitment to compliance and governance.

We are leveraging our deep understanding of smaller Latin American markets through our subsidiaries in the front end, together with our R&D and supply chain excellence at the back end, to create a powerful foundation for expansion into larger markets such as Mexico, Chile, Colombia, and eventually Brazil.

Our relentless emphasis on compliance and operational productivity continues to drive robust growth in regulated markets like the U.S. and Canada, and we expect this segment to represent an even greater share of our business in the coming years. Meanwhile, our China 2.0 strategy positions us to fast-track entry into high-potential areas such as Biosimilars and Peptides — segments traditionally dominated by larger players.

The building blocks we are putting in place from now and over the next couple of year will set Caplin on a strong, multi-year growth trajectory, underpinned by the same consistency, discipline, and performance metrics that have defined us thus far.

***The Company announces the induction of Mr. Ashok Partheeban and Mr. Vivek Partheeban to the Board as Additional Directors, both designated as Vice- Chairman, effective 5th November 2025.***

***The Company also announces the induction of Dr. K C John as Independent Director on its Board, effective 5<sup>th</sup> November 2025.***




## Strategic Growth Initiatives

Project Summary					
Facility	Location	Product	Target Market	Status	Timeline
Caplin Plant I	CP1, Suthukeny, Puducherry	Lyophilized Injectables and Dual Chamber Syringes.	Existing Markets	Nearing Completion	Q3 FY26
API Facility upgradation	Visakhapatnam, Andhra Pradesh	General API	Existing and Regulated Markets	Completed	Completed
Oncology Facility	SIDCO, Kakkalur (Near Chennai)	OSD & Injectable phase	Existing and Regulated Markets	OSD – Completed Injectable – Completed	Completed
Oncology API Facility	Thervoy SIPCOT, Chennai	Oncology API	Existing and Regulated Markets	Civil activity ongoing at full swing.	Q1 FY27
OSD Facility	Puducherry	Oral Solid Dosages	Existing Market along with Mexico, Brazil, US and EU	Design drawing process in progress	Q3 FY27
COL* Injectable Facility	Gummidipoondi, Chennai	Injectables and Ophthalmics	Existing and Regulated Markets	Civil & Structural activity ongoing	Q4 FY27

\*Caplin One Labs Limited

Caplin Point has allocated an enhanced Capex budget of approximately ₹1000 + Crores for the investment projects, with around 50% nearing completion and the balance to be incurred over the next 2-3 years. The intended Capex aims to augment existing production capacities, widen the product range, and achieve backward integration for a majority of the products. The Capex will be financed solely through internal accruals, and the Company will remain net cash positive throughout the process.



### Location of Plants and Facilities

1. SIDCO, Kakkalur, Near Chennai
2. Gummidipoondi, Chennai (CP4)
3. Thervoy SIPCOT, Chennai
4. Corporate Office, Chennai
5. Suthukeny, Puducherry (CP1)
6. APIIC, Visakhapatnam



**About Caplin Point Laboratories Limited:**

Caplin Point Laboratories Limited is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point is one of the few companies to show consistent high-quality growth in Revenues, Profits and Cash flow over the last 15 years. The Company has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company also has a growing presence in the regulated markets such as US through its Subsidiary Caplin Steriles Limited and Caplin Steriles USA Inc.

Caplin Point listed on Forbes “Asia’s 200 Best Under a Billion” list for 2024. Company has appeared for the **SEVENTH** time on this list (2014, 2015, 2016, 2021, 2022, 2023 and 2024) and was awarded “The Emerging Company of 2018” by Economic Times Family Business Awards.

**For further information, please contact:**

**G Venkatram,**  
*General Counsel & Company Secretary*  
Caplin Point Laboratories

+91 44 2496 8000  
[investor@caplinpoint.net](mailto:investor@caplinpoint.net)

**Simran Malhotra / Akshay Hirani**  
Churchgate Partners

+91 22 6169 5988  
[caplinpoint@churchgatepartners.com](mailto:caplinpoint@churchgatepartners.com)

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Caplin Point Laboratories Ltd and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the related industries, increasing competition in and the conditions of the related industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Caplin Point Laboratories Ltd, nor its directors, or any of its subsidiaries/associates assume any obligation to update any forward-looking statement contained in this release.



# EARNINGS PRESENTATION H1 FY26


Rated #1 in India for *"Most Consistent Profitable Growth across the last 10 years"*

*Second Largest wealth creator for the decade ending 2020\**

November 2025 | [www.caplinpoint.net](http://www.caplinpoint.net)








# Evolution Over the Decades








## Contract manufacturer

-  Market-led Company
-  Plain vanilla generic products
-  Introducing products that plugged marketplace gaps
-  Negative-working capital business
-  2 main geographies 10 countries (Latin America & Francophone Africa)


## Becoming a responsible pharma company

-  Technology and research-led marketing Company
-  Mix of generics, branded generics and specialty molecules and Injectables
-  Launch specialty niche products that Create new markets in varied therapy segments
-  Selective use of Credit strategy to increase market share and remain cash surplus
-  Extended to Regulated markets like USA with recent entry into Canada, Australia, Mexico and Brazil shortly


## Diversified Product Portfolio

-  5,000+ Products registered and 650+ Pharmaceutical formulations
-  36 Therapeutic Segments
-  Product mix covers over 65% of WHO essential drug list
-  Latest focus towards complex spaces
-  Accounts for larger shelf share across pharmacies on account of a widening product basket


## Revenue from Operations




## Gross Profit




## EBITDA




## EBIT



## PAT




## Earnings Per Share




(All figures in Rs. Crores except EPS in Rs.)




## Gross Profit Margins (%)




## EBITDA Margins (%)




## EBIT Margins (%)




## PAT Margins (%)




## Revenue from Operations




## Gross Profit




## EBITDA




## EBIT



## PAT



## Profit Margins




(All figures in Rs. Crores)




# H1 FY26 Cash and Cash Equivalents and other Key Metrics

## Cash and Cash Equivalents




## Capital Investment Lifecycle




Cash Flow from  
Operation: ₹ 254 Cr

Free Cashflow: ₹ 160 Cr

## ROE (%)



## ROCE (%)



Receivables: 117 Days

## Chairman Perspectives



Commenting on the recent performance, Mr. C.C. Paarthipan, Chairman of Caplin Point Laboratories said:

*Consistency has been the cornerstone of Caplin's journey. We are pleased to report another strong set of results, fully aligned with our long-term growth path and guidance. Our unwavering focus on cashflows, profitability, and revenue growth continues across all segments of the business, complemented by an equally strong commitment to compliance and governance.*

*We are leveraging our deep understanding of smaller Latin American markets through our subsidiaries in the front end, together with our R&D and supply chain excellence at the back end, to create a powerful foundation for expansion into larger markets such as Mexico, Chile, Colombia, and eventually Brazil.*

*Our relentless emphasis on compliance and operational productivity continues to drive robust growth in regulated markets like the U.S. and Canada, and we expect this segment to represent an even greater share of our business in the coming years. Meanwhile, our China 2.0 strategy positions us to fast-track entry into high-potential areas such as Biosimilars and Peptides – segments traditionally dominated by larger players.*

*The building blocks we are putting in place from now and over the next couple of year will set Caplin on a strong, multi-year growth trajectory, underpinned by the same consistency, discipline, and performance metrics that have defined us thus far.*

## Management Team

Dr. Sridhar Ganesan

- Managing Director



Mr. D Muralidharan

- Chief Financial Officer





# Q2 FY26 Highlights (Emerging Markets)



# Q2 FY26 Highlights (US and Regulated markets)

01

*Company successfully completes EU GMP reaudit in October '25, with NIL Critical Observations.*

02

*Caplin Steriles Limited (CSL) continues consistent and profitable growth in H1 both B2B and B2C segments, aided by timely approvals. Order book remains healthy for H2 to outdo H1 comfortably.*

03

*Company currently sits on 42 ANDA approvals with a further 10 ANDAs under review, setting the stage for strong growth in top and bottom line for the next few quarters.*

04

*CSL has acquired 4 ANDAs from 3rd party companies, and is in advanced discussions to acquire more ANDAs, to augment growing presence in US and other Regulated markets.*

## US & Regulated Markets Business Highlights

*Company's Pre-Filled Syringes and Cartridges Line qualifications completed. Plans to file 11 Pre-Filled Syringe products within the next 12 months, which includes additional SKUs to existing ANDAs. Company will also file GLP-1 products from this line, in Emerging Markets such as Mexico, Colombia, Canada etc.*

05

*Company takes up expansion of Pre-Mixed Injectable Bags line to more than 3X of the current capacity, owing to increased demand from markets and additional approvals.*

06





*Company working on new pipeline of products using BFS technology for Ophthalmics – a niche area with very limited competition.*

07

*Company has started working on COL-II, which is a facility that will house 5 Sterile product lines. This facility will have state-of-the-art equipment with the latest requirements in Aseptic processing technology such as usage of Isolators, dedicated lines, etc. Company plans to commence operations with 2 lines within FY2027.*

08






\*Source – CNBC-TV18, Dec 31st 2020

\*Including Partners and Bought Out


# Revenue Break up and Manufacturing Strategy

FY25 Operating Revenue




Africa US LATAM

Revenue by Business Segment  
(Emerging Markets)



Generic Branded Generic


Revenue by Channel  
(Emerging Markets)



Wholesale Retail Institutional


Caplin covers a wide spectrum of pharmaceutical formulations and therapeutic segments across 23 countries with total revenue of Rs. 2,034 Cr in FY25

Manufacturing & Outsourcing



Inhouse Outsourced

Exports



India China

- The products produced **inhouse**
- The products are **outsourced** from quality-conscious partners in India and China

Caplin's smart strategy of balanced manufacturing and outsourcing makes it possible to be a lean organisation as well as de-risk against cost escalations, currency fluctuations and other headwinds



# Generics and Branded Generics Product Mix



Non-Steroidal Antiinflammatory  
Drugs-NSAIDS



Antihelminthics/ Dewormer



Analgesic



Antibiotic and Antifungal



Antihypertensive drug



Electrolytes

## Caplin Point Laboratories (BSE: 524742| NSE: CAPLIPOINT)

### Manufacturing Units:

- CP I: Puducherry
- CP X: Vishakhapatnam

### Research & Development:

- CP III: Amaris Clinical CRO, Chengalpattu
- CP VI: API's, Intermediates and Key Starting Materials for regulated and semi – regulated markets, Hyderabad
- CP VII: TICEL Bio-Park Bioequivalent dosage forms, Taramani, Chennai
- CP VIII: API's, Intermediates and Key Starting Materials for regulated and semi – regulated markets, Perungudi, Chennai

## Subsidiaries of CPL

- Caplin Point Far East Ltd
- Caplin Steriles Limited (CSL)
- Caplin One Labs Limited (COL)
- Argus Salud Pharma LLP
- Caplin Point (S) Pte Ltd

## Caplin Point Far East Ltd

### Subsidiaries

- Nuevos Eticos Neo Ethicals S.A. Guatemala
- Neo Ethicals S.A. Nicaragua
- Drogueria Saimed de Honduras S.A
- Caplin Point El Salvador, S.A. DE C.V.
- Neoethicals CIA. LTDA Ecuador
- Caplin Point Laboratories Colombia SAS
- Neo Ethicals Chile SpA.
- Triwin Pharma S.A DE C.V Mexico

## Caplin One Labs Ltd (COL)

### Manufacturing Unit:

- SIDCO, Kakkalur (Near Chennai)
- Gummidipoondi, Chennai

## Caplin Steriles Ltd (India)

### Manufacturing Units:

- CP IV: Gummidipoondi

### Research & Development:

- Perungudi, Chennai
- Gummidipoondi

- Sunsole Solar Private Ltd (Associate of CSL)


## Caplin Steriles USA Inc (US)

### Distribution:

- Front-end trading arm for the sale of products in the USA



Tamil Nadu, India



## Location of Plants and Facilities

1. SIDCO, Kakkalur, Near Chennai
2. Gummidipoondi, Chennai
3. Thervoy SIPCOT, Chennai
4. Corporate Office, Chennai
5. Suthukeny, Puducherry
6. APIIC, Visakhapatnam

Andhra Pradesh, India



CP I  
Puducherry



CP III  
Chengalpattu



CP IV  
Gummidipoondi



CP VI  
Hyderabad



Corporate Office and other  
R&D units:  
Chennai



CP VII  
Chennai

Note. CP III and CP VII are for Research and Development

Project Summary					
Facility	Location	Product	Target Market	Status	Timeline
Caplin Plant I	CP1, Suthukeny, Puducherry	Lyophilized Injectables and Dual Chamber Syringes.	Existing Markets	Nearing Completion	Q3 FY26
API Facility upgradation	Visakhapatnam, Andhra Pradesh	General API	Existing and Regulated Markets	Completed	Completed
Oncology Facility	SIDCO, Kakkalur (Near Chennai)	OSD & Injectable phase	Existing and Regulated Markets	OSD –Injectable Completed	Completed
Oncology API Facility	Thervoy SIPCOT, Chennai	Oncology API	Existing and Regulated Markets	Civil activity ongoing at full swing	Q1 FY27
OSD Facility	Puducherry	Oral Solid Dosages	Existing Market along with Mexico, Brazil, US and EU	Design drawing process in progress	Q3 FY27
COL* Injectable Facility	Gummidipoondi, Chennai	Injectables and Ophthalmics	Existing and Regulated Markets	Civil & Structural activity ongoing	Q4 FY27

\* Caplin One Labs Limited

Caplin Point has allocated an enhanced Capex budget of approximately Rs.1,000 + Crores for the investment projects, with around 50% nearing completion and the balance to be incurred over the next 2–3 years. The intended Capex aims to augment existing production capacities, widen the product range, and achieve backward integration for a majority of the products. The Capex will be financed solely through internal accruals, and the Company will remain net cash positive throughout the process



## Core Business to show consistent growth

Caplin's core business which is focused on Latin America and Francophone Africa is expected to grow at a steady pace with industry-average margins and benchmark cashflows

## US Business to Boost the Growth

Aspiration is to have exceptional compliance record and focus on niche products which continues to be in shortage in US market. Caplin believes US business to be one of its primary engines that will drive growth

## Backed by Enhanced Value Chain

Backward and forward integration to help save cost, capture more market and control supply chain which is expected to boost earnings

## Strong Balance Sheet

Caplin's DNA of remaining debt-free and self-sustenance is highlighted by increasing cash surplus over the years. Strong Balance sheet of Caplin acts as an anchor for our long-term vision

## Expansion into Other Geographies and Widening of the Portfolio

Caplin plans to enter more regulated markets such as Canada, Australia, MENA, Russia/CIS as well as enter the bigger LATAM markets of Mexico and Brazil in the near to medium term horizon

Strong operational performance driven by key pillars of Caplin's Engines

# Experienced and Visionary Board of Directors (1/2)



**Mr. C.C. Paarhipan**  
*Chairman*

30+ Years of experience in the pharmaceutical industry

Spearheading the group in its multi-pronged growth approach

First Gen Entrepreneur with a focus towards bottom of the pyramid



**Dr. Sridhar Ganesan**  
*Managing Director*

35+ Years experience in Pharmaceutical Industry

Previously, held leadership positions in several international assignments

The Government of India's Pharmaceutical Export Promotion Council of India has designated him as an "Honorary Expert"

Has been a Faculty in BITS



**Mr. Vivek Partheeban**  
*Vice Chairman*

20+ years of experience in the pharmaceutical industry

Was COO at Caplin Point Laboratories Ltd. Oversees the entire US/regulated market operations

Educated at Harvard Business School and Monash University

Honorary Consul for the Republic of Guatemala in Chennai since 2018



**Mr. Ashok Partheeban**  
*Vice Chairman*

23+ Years experience in Pharmaceutical Industry

Oversees the entire LATAM operations since 2002 as well as other emerging markets.

Spearheaded market expansion and growth initiatives in the LATAM region

Holds an Associate's Degree in OPM from Harvard Business School and a Bachelor's in Marketing from Middlesex University



**Dr. KC John**  
*Independent Director*

35+ years of experience in sustainable development

Held leadership roles in start-ups, tech ventures, and acquisitions

Expert member on the investment committee of Tamil Nadu Industrial Development Corporation

Doctorate in Management from Indian Institute of Management, Ahmedabad



# Experienced and Visionary Board of Directors (2/2)



**Dr. C K Gariyali, IAS**  
*Independent Director*

Retired IAS Officer  
and holds a  
Doctorate in  
Women Studies

Was Principal  
Secretary to the  
Governor of Tamil  
Nadu from 2005-  
08

Was Secretary to  
Hon'ble CM of Tamil  
Nadu

Worked with  
various International  
Agencies like World  
Bank etc.



**Dr. R Nagendran**  
*Independent Director*

Ph.D in Ecology and  
Ethology and M.SC in  
Zoology

Former Expert  
Member of the  
National Green  
Tribunal and former  
Head of Department  
of Environmental  
Science in St. Joseph's  
College, Bangalore.



**Mr S Deenadayalan**  
*Independent Director*

Post Graduate degree  
in Social Work from  
Madras School of  
Social Work and Under  
Graduate degree in  
Sociology from  
Annamalai University

Has extensively  
worked and mentors  
individuals enabling  
them to become  
successful  
professionals and more  
than 30,000 municipal  
school students have  
been benefitted by his  
idealistic model.



**Mr. R. Vijayaraghavan**  
*Independent Director*

35+ years of experience  
as a taxation expert with  
consulting and litigation  
practice across India

Advises major corporate  
groups in South India on  
Direct Taxes, Tax  
Planning, Tax Litigations

Specializes in advising  
on taxation of non-  
residents, joint ventures  
& collaborations, double  
taxation avoidance  
agreements & transfer  
pricing issues.

# Q2 FY26 Consolidated Income Statement

(Rs. in Cr)	Q2 FY26	Q2 FY25	YoY (%)	Q1 FY26	QoQ (%)	H1 FY26	H1 FY25	YoY (%)
Revenue from Operation	534.04	483.10	10.5%	510.22	4.7%	1,044.26	942.06	10.8%
Other Income	30.37	20.77	46.2%	23.14	31.2%	53.51	39.33	36.1%
<b>Total Revenue</b>	<b>564.41</b>	<b>503.87</b>	<b>12.0%</b>	<b>533.36</b>	<b>5.8%</b>	<b>1,097.77</b>	<b>981.39</b>	<b>11.9%</b>
Cost of Goods sold	210.30	188.82	11.4%	195.24	7.7%	405.54	374.30	8.3%
<b>Gross Profit (Excluding Other Income)</b>	<b>323.74</b>	<b>294.28</b>	<b>10.0%</b>	<b>314.98</b>	<b>2.8%</b>	<b>638.72</b>	<b>567.76</b>	<b>12.5%</b>
<i>Gross Profit Margin (on Rev from Operations)</i>	<b>60.6%</b>	<b>60.9%</b>		<b>61.7%</b>		<b>61.2%</b>	<b>60.3%</b>	
Employee Benefit Expenses	47.23	44.29	6.6%	43.16	9.4%	90.39	84.44	7.0%
Research and Development expenses	21.45	19.64	9.2%	17.96	19.4%	39.41	38.84	1.5%
Other operating expenses	65.89	65.59	0.5%	76.10	(13.4)%	141.99	127.91	11.0%
<b>Total expenditure</b>	<b>134.57</b>	<b>129.52</b>	<b>3.9%</b>	<b>137.22</b>	<b>(1.9)%</b>	<b>271.79</b>	<b>251.19</b>	<b>8.2%</b>
<b>EBITDA</b>	<b>219.54</b>	<b>185.53</b>	<b>18.3%</b>	<b>200.90</b>	<b>9.3%</b>	<b>420.44</b>	<b>355.90</b>	<b>18.1%</b>
<i>EBITDA Margin</i>	<b>38.9%</b>	<b>36.8%</b>		<b>37.7%</b>		<b>38.3%</b>	<b>36.3%</b>	
Depreciation and Amortisation	18.40	16.76	9.8%	16.29	13.0%	34.69	32.72	6.0%
<b>EBIT</b>	<b>201.14</b>	<b>168.77</b>	<b>19.2%</b>	<b>184.61</b>	<b>9.0%</b>	<b>385.75</b>	<b>323.18</b>	<b>19.4%</b>
<i>EBIT Margin</i>	<b>35.6%</b>	<b>33.5%</b>		<b>34.6%</b>		<b>35.1%</b>	<b>32.9%</b>	
Finance Cost	0.16	0.21		0.18		0.34	0.26	
Share of Profit/(Loss) in associates	0.02	(0.10)		0.03		0.05	(0.08)	
<b>Profit Before Tax</b>	<b>201.00</b>	<b>168.46</b>	<b>19.3%</b>	<b>184.46</b>	<b>9.0%</b>	<b>385.46</b>	<b>322.84</b>	<b>19.4%</b>
<i>PBT Margin</i>	<b>35.6%</b>	<b>33.4%</b>		<b>34.6%</b>		<b>35.1%</b>	<b>32.9%</b>	
Tax	40.77	37.65	8.3%	33.70	21.0%	74.47	67.11	11.0%
<b>Profit after Tax</b>	<b>160.23</b>	<b>130.81</b>	<b>22.5%</b>	<b>150.76</b>	<b>6.3%</b>	<b>310.99</b>	<b>255.73</b>	<b>21.6%</b>
<i>PAT Margin</i>	<b>28.4%</b>	<b>26.0%</b>		<b>28.3%</b>		<b>28.3%</b>	<b>26.1%</b>	

# Visit Our Real Time ESG Disclosure Platform

At the core of our ethos lies a steadfast commitment to embedding environmental, social, and governance principles into our operations.

Map our ESG framework with 35+ different frameworks

Download ESG data

Access to ESG factsheet

Search for keywords

Over 12 factors and 400+ KPI

Click to access ESG Profile

Caplin Point Providing Remedies  
**BRINGING SMILES**  
To People

Caplin Point Laboratories

Home The Company Infrastructure Products Investors Sustainability Careers Contact Us

CSR Trust  
CSR Activities  
Policies  
ESG Profile

Caplin Point ESG Profile Link ([Click Here](#))

<https://www.caplinpoint.net/>



ESG Commitments



**Community Development**

- ✓ Caplin Group’s state-of-the-art hospital and diagnostic centre at Gummidipoondi, Chennai



**Recycled Waste**

- ✓ 60.2 MT waste recycled in 2025



**Environmental & Social**

- ✓ Low carbon footprint
- ✓ Women empowerment
- ✓ Investments in rural healthcare

CSR

**INR 8.49 Crores**

Amount spent on CSR in FY25

**INR 3.19 Crores**

Amount spent on CSR upto H1FY26

The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Caplin Point Laboratories Ltd.



**Mr G Venkatram**

[investors@caplinpoint.net](mailto:investors@caplinpoint.net)

**Churchgate  
Investor Relations**

**Simran Malhotra / Akshay Hirani**

[caplinpoint@churchgatepartners.com](mailto:caplinpoint@churchgatepartners.com)

**BSE** 524742

**NSE** CAPLIPOINT

**CIN:** L24231TN1990PLC019053

**ISIN:** INE475E01026 | **DUNS:** 86-148-4556 | [WWW.CAPLINPOINT.NET](http://WWW.CAPLINPOINT.NET)

©2018, Caplin Point Laboratories Limited – All Rights Reserved.

“Caplin Point” and The Caplin Point Logo are trademarks of Caplin Point Laboratories Limited. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.

